GoodRx Holdings, Inc. (NASDAQ:GDRX), a leader in consumer-focused digital healthcare platforms with impressive gross profit margins of 94%, announced the appointment of Scott Wagner as a Class II ...

SANTA MONICA, Calif. - GoodRx Holdings, Inc. (NASDAQ:GDRX), a leading U.S. prescription savings platform, announced the appointment of Scott Wagner as Co-Chair of its Board of Directors, effective ...

GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced that Scott Wagner has joined its Board of ...

Explore GoodRx's innovative new service designed to make pet care more affordable and accessible for pet owners.

Shares of GoodRx have fallen ~20% over the past year. Amid hopes for growth via direct relationships with pharmaceutical manufacturers, the company may have hit a near-term bottom. GDRX returned ...

BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

Pet owners now have a new online resource that can help them save money. GoodRx, a company known for offering consumers ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

GoodRx (GDRX) said in a regulatory filing that on January 7, Karsten Voermann submitted his resignation as Chief Financial Officer of GoodRx, ...

In a disclaimer, GoodRx noted that the list was created by prioritizing "first-in-class medications and vaccines that are expected to have a significant impact on human health." "This was defined ...

Goodrx Holdings Inc (GDRX) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.15 or 3.39% from the prior close of $4.42. The stock opened at $4.41 and touched ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.